ATE181328T1 - 5-(phenyl)-3-(4-piperidinyl)-1,3,4-oxadiazol- 2(3h)-on-derivate verwendbar als 5-ht4- oder h3- rezeptorliganden - Google Patents

5-(phenyl)-3-(4-piperidinyl)-1,3,4-oxadiazol- 2(3h)-on-derivate verwendbar als 5-ht4- oder h3- rezeptorliganden

Info

Publication number
ATE181328T1
ATE181328T1 AT96937390T AT96937390T ATE181328T1 AT E181328 T1 ATE181328 T1 AT E181328T1 AT 96937390 T AT96937390 T AT 96937390T AT 96937390 T AT96937390 T AT 96937390T AT E181328 T1 ATE181328 T1 AT E181328T1
Authority
AT
Austria
Prior art keywords
oxadiazole
piperidinyl
phenyl
receptor ligands
derivatives usable
Prior art date
Application number
AT96937390T
Other languages
English (en)
Inventor
Samir Jegham
Alistair Lochead
Frederic Galli
Alain Nedelec
Axelle Solignac
Cruz Laurence De
Original Assignee
Synthelabo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR9513253A external-priority patent/FR2741070B1/fr
Priority claimed from FR9513252A external-priority patent/FR2741069B1/fr
Priority claimed from FR9602663A external-priority patent/FR2745574B1/fr
Application filed by Synthelabo filed Critical Synthelabo
Application granted granted Critical
Publication of ATE181328T1 publication Critical patent/ATE181328T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
AT96937390T 1995-11-09 1996-11-05 5-(phenyl)-3-(4-piperidinyl)-1,3,4-oxadiazol- 2(3h)-on-derivate verwendbar als 5-ht4- oder h3- rezeptorliganden ATE181328T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9513253A FR2741070B1 (fr) 1995-11-09 1995-11-09 Derives de 5-phenyl-3-(piperidin-4-yl)-1,3,4-oxadiazol-2(3h) -one, leur preparation et leur application en therapeutique
FR9513252A FR2741069B1 (fr) 1995-11-09 1995-11-09 Derives de 5-phenyl-3-(piperidin-4-yl)-1,3,4-oxadiazol-2(3h) -one, leur preparation et leur application en therapeutique
FR9602663A FR2745574B1 (fr) 1996-03-04 1996-03-04 Derives de 5-phenyl-3-(piperidin-4-yl)-1, 3, 4-oxadiazol-2 (3h)-one, leur preparation et leur application en therapeutique

Publications (1)

Publication Number Publication Date
ATE181328T1 true ATE181328T1 (de) 1999-07-15

Family

ID=27253120

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96937390T ATE181328T1 (de) 1995-11-09 1996-11-05 5-(phenyl)-3-(4-piperidinyl)-1,3,4-oxadiazol- 2(3h)-on-derivate verwendbar als 5-ht4- oder h3- rezeptorliganden

Country Status (29)

Country Link
US (1) US5929089A (de)
EP (1) EP0863897B1 (de)
JP (1) JP4263240B2 (de)
CN (1) CN1077891C (de)
AR (1) AR004708A1 (de)
AT (1) ATE181328T1 (de)
AU (1) AU707325B2 (de)
BG (1) BG63463B1 (de)
BR (1) BR9611311A (de)
CA (1) CA2236357C (de)
CO (1) CO4770968A1 (de)
CZ (1) CZ287268B6 (de)
DE (1) DE69602970T2 (de)
EE (1) EE03487B1 (de)
ES (1) ES2135934T3 (de)
GR (1) GR3030823T3 (de)
HU (1) HUP0001168A3 (de)
IL (1) IL124364A (de)
MX (1) MX9803696A (de)
NO (1) NO309606B1 (de)
NZ (1) NZ321626A (de)
PL (1) PL186204B1 (de)
RU (1) RU2167160C2 (de)
SI (1) SI0863897T1 (de)
SK (1) SK282335B6 (de)
TR (1) TR199800827T2 (de)
TW (1) TW371303B (de)
UA (1) UA50748C2 (de)
WO (1) WO1997017345A1 (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW467902B (en) 1996-07-31 2001-12-11 Bristol Myers Squibb Co Diphenyl heterocycles as potassium channel modulators
FR2762316B1 (fr) * 1997-04-18 1999-12-17 Sanofi Synthelabo Derives de 5-aryl-3-(8-azabicyclo[3.2.1] octan-3-yl)-1,3,4- oxadiazol-2(3h)-one, leur preparation et leur application en therapeutique
WO1998050383A1 (fr) * 1997-05-06 1998-11-12 Sanofi-Synthelabo Derives de 5-phenyl-1,3,4-oxadiazol-2(3h)-one et leur utilisation comme ligands 5-ht4
FR2763068B1 (fr) * 1997-05-06 1999-06-04 Synthelabo Derives de 3-(pyrrolidin-3-yl)-1,3,4-oxadiazol-2(3h)-one, leur preparation et leur application en therapeutique
GB9715816D0 (en) * 1997-07-25 1997-10-01 Black James Foundation Histamine H receptor ligands
US6960579B1 (en) 1998-05-19 2005-11-01 Alcon Manufacturing, Ltd. Serotonergic 5HT7 receptor compounds for treating ocular and CNS disorders
AU755119B2 (en) 1998-09-18 2002-12-05 Alcon Laboratories, Inc. Serotonergic 5HT2 agonists for treating glaucoma
WO2000064441A2 (en) * 1999-04-28 2000-11-02 Respiratorius Ab Compound for use as a medicament for treatment of disorders involving bronchocontraction
CN1355698A (zh) * 1999-06-15 2002-06-26 呼吸器有限公司 可用作治疗有关支气管收缩的机能障碍的药物的化合物
US6638967B2 (en) 2000-08-08 2003-10-28 Ortho-Mcneil Phamraceutical, Inc. Thiophene of furan pyrrolidine compounds
CA2418369A1 (en) 2000-08-08 2002-02-14 Richard Apodaca Non-imidazole aryloxyalkylamines as h3 receptor ligands
CZ2003686A3 (cs) * 2000-08-08 2003-08-13 Ortho Mcneil Pharmaceutical, Inc. Neimidazolové aryloxypiperidiny
US7208497B2 (en) 2001-07-02 2007-04-24 Novo Nordisk A/S Substituted piperazines and diazepanes
WO2003004480A2 (en) 2001-07-02 2003-01-16 Novo Nordisk A/S Substituted piperazine and diazepanes as histamine h3 receptor agonists
EP1434765B1 (de) * 2001-09-14 2009-12-02 High Point Pharmaceuticals, LLC Substituierte piperidinen mit selektiver bindungsfähigkeit zu histamin h3-rezeptoren
US20030186963A1 (en) 2001-09-14 2003-10-02 Dorwald Florencio Zaragoza Substituted piperidines
US6673829B2 (en) 2001-09-14 2004-01-06 Novo Nordisk A/S Aminoazetidine,-pyrrolidine and -piperidine derivatives
JP4619655B2 (ja) 2001-09-14 2011-01-26 ハイ・ポイント・ファーマスーティカルズ、エルエルシー 新規アミノアゼチジン、−ピロリジンおよび−ピペリジン誘導体
US7064135B2 (en) 2001-10-12 2006-06-20 Novo Nordisk Inc. Substituted piperidines
WO2003031432A1 (en) 2001-10-12 2003-04-17 Novo Nordisk A/S Substituted piperidines and their use for the treatment of diseases related to the histamine h3 receptor
JP2005511764A (ja) 2001-12-14 2005-04-28 アルコン，インコーポレイテッド 緑内障の処置のためのアミノアルキルベンゾフラン−５−オール化合物
US20030236259A1 (en) * 2002-02-05 2003-12-25 Rolf Hohlweg Novel aryl- and heteroarylpiperazines
GB0211230D0 (en) * 2002-05-16 2002-06-26 Medinnova Sf Treatment of heart failure
US7332508B2 (en) * 2002-12-18 2008-02-19 Novo Nordisk A/S Substituted homopiperidine, piperidine or pyrrolidine derivatives
GB0325956D0 (en) * 2003-11-06 2003-12-10 Addex Pharmaceuticals Sa Novel compounds
EA200801607A1 (ru) 2004-06-15 2008-10-30 Пфайзер Инк. Производные бензимидазолонкарбоновой кислоты
US7737163B2 (en) 2004-06-15 2010-06-15 Pfizer Inc. Benzimidazolone carboxylic acid derivatives
CN103110635A (zh) * 2005-07-04 2013-05-22 海波因特制药有限责任公司 组胺h3受体拮抗剂
DE602006011363D1 (de) * 2005-12-01 2010-02-04 Hoffmann La Roche Heteroaryl-substituierte piperidin-derivate als l-cpt1-hemmer
ATE538116T1 (de) * 2006-05-29 2012-01-15 High Point Pharmaceuticals Llc 3-(1,3-benyodioxol-5-yl)-6- (4- cyclopropylpiperazin-1-yl)-pyridazin, dessen salze und solvate und dessen verwendung als histamin-h3-rezeptorantagonist
EP2014656A3 (de) 2007-06-11 2011-08-24 High Point Pharmaceuticals, LLC Neue heterocyclische H3-Antagonisten
DK2758394T3 (en) * 2011-09-19 2015-04-20 Suven Life Sciences Ltd HETEROARYL COMPOUNDS AS 5-HT4 RECEPTOR LIGANDS

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5055476A (en) * 1990-08-13 1991-10-08 Hoechst-Roussel Pharmaceuticals Incorporated 3-(1,2-benzisoxazol-3-yl)-4-pyridinamines and derivatives
NZ243993A (en) * 1991-08-20 1994-10-26 Smithkline Beecham Plc Pharmaceutical compositions having 5-ht4 receptor antagonist activity and selected compounds having such activity
ES2135414T3 (es) * 1991-09-12 1999-11-01 Smithkline Beecham Plc Antagonistas del receptor 5-ht4.
CA2129112A1 (en) * 1992-02-06 1993-08-19 Francis David King Benzopyran, benzothiopyran and benzofuran derivatives as 5-ht4 antagonists
GB9219163D0 (en) * 1992-09-10 1992-10-28 Smithkline Beecham Plc Pharmaceuticals
JPH06157518A (ja) * 1992-11-27 1994-06-03 Yamanouchi Pharmaceut Co Ltd 新規なオキサジアゾール誘導体又はその塩

Also Published As

Publication number Publication date
BG63463B1 (bg) 2002-02-28
AR004708A1 (es) 1999-03-10
TW371303B (en) 1999-10-01
CN1202169A (zh) 1998-12-16
AU7500196A (en) 1997-05-29
PL326671A1 (en) 1998-10-12
US5929089A (en) 1999-07-27
WO1997017345A1 (fr) 1997-05-15
CZ287268B6 (en) 2000-10-11
EE9800155A (et) 1998-12-15
HUP0001168A2 (hu) 2001-04-28
BG102412A (en) 1999-08-31
EP0863897A1 (de) 1998-09-16
JP2000500125A (ja) 2000-01-11
DE69602970D1 (de) 1999-07-22
HK1016165A1 (en) 1999-10-29
ES2135934T3 (es) 1999-11-01
MX9803696A (es) 1998-09-30
SK59998A3 (en) 1998-11-04
CN1077891C (zh) 2002-01-16
IL124364A0 (en) 1998-12-06
JP4263240B2 (ja) 2009-05-13
RU2167160C2 (ru) 2001-05-20
NO309606B1 (no) 2001-02-26
DE69602970T2 (de) 2000-01-20
IL124364A (en) 2001-08-08
UA50748C2 (uk) 2002-11-15
CZ142198A3 (cs) 1998-08-12
SI0863897T1 (en) 1999-10-31
NO982092L (no) 1998-06-29
NZ321626A (en) 1998-10-28
HUP0001168A3 (en) 2001-07-30
NO982092D0 (no) 1998-05-07
EE03487B1 (et) 2001-08-15
EP0863897B1 (de) 1999-06-16
BR9611311A (pt) 1999-06-29
PL186204B1 (pl) 2003-11-28
SK282335B6 (sk) 2002-01-07
GR3030823T3 (en) 1999-11-30
AU707325B2 (en) 1999-07-08
TR199800827T2 (xx) 1999-02-22
CO4770968A1 (es) 1999-04-30
CA2236357C (en) 2006-10-17
CA2236357A1 (en) 1997-05-15

Similar Documents

Publication Publication Date Title
DE69602970D1 (de) 5-(phenyl)-3-(4-piperidinyl)-1,3,4-oxadiazol-2(3h)-on-derivate verwendbar als 5-ht4- oder h3-rezeptorliganden
DE59810228D1 (de) Phenylalkylderivate mit thrombinhemmender wirkung
BR9804865A (pt) Pesticida 3-(fenil substitu¡do)-5-(tirnil ou furil)-1,2,4-triazÄis
DK0733628T3 (da) 5-substituerede 3-(1,2,3,6-tetrahydropyridin-4-yl)- og 3-(piperidin-4-yl)-1H-indoler: 5HT1F-agonister
DK0876359T3 (da) (-)-cis-6(S)-phenyl-5(R)- [4-(2-pyrrolidin-1-ylethoxy)phenyl]-5,6,7,8-tetrahydronaphthalen-2-ol-D-tartrat
IS5336A (is) 2-(4-Arýl eða heteróarýl-píperazín-1-ýlmetýl)-1H-indól afleiður
FI921925A7 (fi) Kemiluminescerande 3-(substituerad adamant-2-yliden)-1,2-dioxetaner.
ATE206424T1 (de) 5-aryl-3-(8-azabicyclo(3.2.1)oct-3-yl)-1,3,4- oxadiazol-2(3h)-one derivate als 5-ht4 rezeptor liganden
TR200101119T2 (tr) Beyaz sineğe karşı aktiviteye sahip 3-(sübstitüe fenil)-5-tienil-1,2,4-triazol bileşikleri
FI920776A7 (fi) Foerfarande foer framstaellning av nya terapeutiskt anvaendbara 5-(substituerad amino)-1,2,4-triazolo-(1,5-a)pyrimidinderivat
ATE205049T1 (de) Potenzierung von dem 2-(thiocyanomethylthio)- benzothiazol-mikrobizid unter verwendung von einer n-alkyl heterocyclischen verbindung
NO954892L (no) Heterosyklisk kjemi
MXPA03000186A (es) Comuestos de 2-(3,5-disustituido-4-piridil)-4-(tienilo, tiazolilo o arilfenil)-1,3-oxazolina.
FI923723L (fi) 4-(4-(4-(-hydroxifenyl)-1-piperazinyl)fenyl)-5-metyl-3h-1,2,4-triazol-3-on derivat
BR9206862A (pt) Compostos herbicidas e fungicidas,derivados de azol, e, composição herbicida e/ou fungicida
PT1123281E (pt) Compostos 3-(fenil substituido)-5-(ciclopropil substituido)1,2,4-triazole
PL326630A1 (en) Methods of obtaining 3-(1-piperasinyl)-1,2-benzoisothiazole and novel initial compounds therefor
BR9506518A (pt) Derivados de 3-aril-alquenil- 1,2,4-oxadiazol
DK0863897T3 (da) Derivater af 5-phenyl-3-(piperidin-4-yl)-1,3,4-oxadiazol-2(3H)-on, som kan anvendes som ligander for 5-HT4- eller H3-recept
ZA891310B (en) 5-(substituted-amino)-8-(phenyl or substituted-phenyl)-3h,6h-1,4,5a,8a-tetraazaacenaphthyen-3-ones
NO996580D0 (no) 5-(2-etyl-2H-tetrazol-5-yl)-1-metyl-1,2,3,6- tetrahydropyridinmaleat
ATE252577T1 (de) 3-(3-pyrrolidinyl)-2(3h)-1,3,4- oxadiazolonderivate und ihre verwendung als 5-ht4 liganden
FR2759699B1 (fr) Derives de 5-(2,3-dihydro-1,4-benzoxazin-5-yl)-3-(piperidin- 4-yl)-1,3,4-oxadiazol-2(3h)-one, leur preparation et leur application en therapeutique
DE69803654D1 (de) Pestizide 3-(substituiertes phenyl)-5-(thienyl oder furyl)-1,2,4-triazole

Legal Events

Date Code Title Description
EEIH Change in the person of patent owner
UEP Publication of translation of european patent specification